Drugs / TDENV-PIV
TDENV-PIV
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03141138 | Nov 2017 → Oct 2019 | dengue disease | U.S. Army Medical Research and Development Command | Unknown | No outcome recorded |
| Phase 1 | NCT03110952 | Jan 2016 → Apr 2017 | dengue disease | U.S. Army Medical Research and Development Command | Withdrawn | No outcome recorded |
| Phase 1 | NCT02239614 | Dec 2014 → Feb 2016 | dengue disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1 | NCT01702857 | Nov 2012 → Jan 2017 | dengue disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1 | NCT01666652 | Sep 2012 → Sep 2015 | dengue disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02421367 | Aug 2015 → Dec 2016 | dengue disease | U.S. Army Medical Research and Development Command | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDENV-PIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110952 ↗ |
| Known as | DPIV | “AbstractThe safety and immunogenicity of four formulations of an investigational tetravalent dengue purified inactivated vaccine (DPIV), formulated at 1 or 4 μg with aluminum...” PMID 28719287 ↗ Jun 2017 |
| Known as | DPIV+AS03B | “We evaluated three dosing regimens of the investigational tetravalent AS03B-adjuvanted dengue-purified inactivated vaccine (DPIV+AS03B).” PMID 32342848 ↗ Apr 2020 |
| Known as | Tetravalent Dengue Virus Purified Inactivated Vaccine | “A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of Walter Reed Army Institute of Research (WRAIR) Tetravalent...” NCT01666652 ↗ |
| Known as | Tetravalent dengue virus, purified inactivated vaccine, TDENV-PIV with AS03B adjuvant | “Tetravalent dengue virus, purified inactivated vaccine, TDENV-PIV with AS03B adjuvant” NCT03110952 ↗ |
| Modality | Vaccine | “four formulations of an investigational tetravalent dengue purified inactivated vaccine (DPIV)” PMID 28719287 ↗ Jun 2017 |
| Route | Intramuscular | “0.5 mL intramuscular injection at 0 and 28 days” NCT01666652 ↗ |